Plaque Psoriasis

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, review use of nonbiologic oral systemic agents (eg, apremilast, methotrexate, acitretin) in the management of plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, discuss the current role of topical medications as the standard of care for initial therapy in plaque psoriasis.

Linda F. Stein Gold, MD, delves into the psychosocial impacts of living with plaque psoriasis.

Mark Lebwohl, MD, and Jerry Bagel, MD, MS, provide an overview of the pathogenesis of and comorbidities associated with plaque psoriasis.

Investigators added that clinical condition at the time of vaccination and biologic treatment did not influence the humoral response in the enrolled patients.

Lifestyle modification and counseling to help manage flare-ups resulting from triggers for plaque psoriasis.

Diagnosis and management of plaque psoriasis as discussed by advanced practice providers.

Dr. Amy Paller and colleagues noted high efficacy rates and minimal adverse events from biologic therapy.

The topical drug was associated with adverse events that were mainly localized to the application site and mild to moderate in nature.

The condition is rare, with limited epidemiological data and no standard treatment.

Advanced practice providers share their perspectives on assessing and grading the disease severity of plaque psoriasis.

Erin Boh, MD, PhD, FAAD, shares insight into clinical manifestations of plaque psoriasis, and panelists emphasize how disease characteristics may be mistaken for signs and symptoms of commonly comorbid diseases.

The clinical and psychological impact of plaque psoriasis on a patient’s overall well-being.

An expert dermatologist, George Han, MD, PhD, provides a brief overview of the pathogenesis of plaque psoriasis and reviews some common environmental triggers.

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.

Investigators stated that prolonged maintenance dosing of the monoclonal antibody was preferred by affected patients.

Investigators reported that the efficacy of the medication is supported by a high safety profile, with fleeting and limited adverse events recorded.

Investigators reported that a higher proportion of participants in the abatacept group relapsed between weeks 12 and 40 compared to participants in the ustekinumab group.

Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.

The treatment was approved for adult patients with plaque psoriasis in 2018.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.